ClinicalTrials.gg

TargetBeta

ALK

ALK receptor tyrosine kinase · also CD246, ALK1 · CD molecules

10 programs in company-led studies act on ALK, from 9 companies: 4 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
lorlatinibrulePfizerphase 4205 runningEML4NCIt
CrizotinibrulePfizerphase 4312 runningEML4, MET, MST1R, NPM1, ROS1NCIt
ensartinibruleBetta Pharmaceuticalsphase 3125 running–NCIt
repotrectinibruleBristol-Myers Squibbphase 393 runningCD74, NTRK1, NTRK2, NTRK3, PTK2, ROS1, SDC4, SRCNCIt
gilteritinibruleAstellas Pharmaphase 3202 runningAXL, FLT3, LTKNCIt
neladalkibGlaxoSmithKlinephase 322 running–the company's pipeline
ALK Molecular Glue Degrader TRI-611ruleTRIANA Biomedicinesphase 211 running–NCIt
Foritinib SuccinateFosun Pharmaphase 211 running–the company's pipeline
AQUA07Hoffmann-La Rochephase 111 running–the company's pipeline
SIM0518ruleSimcere Pharmaceutical Groupphase 111 runningROS1the studies' text

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.